ANDA 70092, held by Igi Labs Inc. Dopamine Hydrochloride.
As of Nov 16, 2026, ANDA 70092 (Dopamine Hydrochloride), held by Igi Labs Inc, was first approved by FDA on Oct 23, 1985, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 1985 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dopamine Hydrochloride160MG/ML ยท injectable;injection | Dopamine Hydrochloride | Discontinued |
| Jul 17, 2002 | Supplement 11Labeling | Approved | None posted |
| Oct 3, 1996 | Supplement 10Labeling | Approved | None posted |
| Jun 2, 1992 | Supplement 9Labeling | Approved | None posted |
| Sep 30, 1991 | Supplement 7Manufacturing | Approved | None posted |
| Sep 30, 1991 | Supplement 8Manufacturing | Approved | None posted |
| Aug 3, 1988 | Supplement 5Manufacturing | Approved | None posted |
| Aug 3, 1988 | Supplement 6Manufacturing | Approved | None posted |
| Mar 31, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Oct 23, 1985 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters